(Q38205127)

31 August 2017

Management options in locally advanced pancreatic cancer (English)

1 reference

31 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24740136%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

Ashwin N Ram

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24740136%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Richard Tuli

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24740136%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Joseph M Herman

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24740136%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

publication date

1 June 2014

1 reference

31 August 2017

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24740136%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24740136%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24740136%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

388

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24740136%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11912-014-0388-y

14 June 2020

exact match

0 references

cites work

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Stomach-preserving distal pancreatectomy with combined resection of the celiac artery: radical procedure for locally advanced cancer of the pancreatic body.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

The pancreas cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Stromal biology and therapy in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

How to define and manage borderline resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Therapeutic advances in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

The role of intraoperative radiotherapy in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Intraoperative radiotherapy for pancreatic cancer: 30-year experience in a single institution in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Pancreaticoduodenectomy with vascular resection: margin status and survival duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0388-Y

Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma

21 January 2018

1 reference

12 December 2020

The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.

1 reference

12 December 2020

1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience

1 reference

12 December 2020

Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis

1 reference

12 December 2020

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

12 December 2020

Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002)

1 reference

12 December 2020

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

1 reference

12 December 2020

Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas

1 reference

12 December 2020

Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma

1 reference

12 December 2020

Induction Gemcitabine and Stereotactic Body Radiotherapy for Locally Advanced Nonmetastatic Pancreas Cancer

1 reference

12 December 2020

Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer

1 reference

12 December 2020

Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability

1 reference

12 December 2020

Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group

1 reference

12 December 2020

Borderline resectable pancreatic cancer: what have we learned and where do we go from here?

1 reference

12 December 2020

More than the sum of its parts: how multidisciplinary cancer care can benefit patients, providers, and health systems

1 reference

12 December 2020

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.

1 reference

12 December 2020